Premature Ticagrelor Discontinuation in Secondary Prevention of Atherosclerotic CVD: JACC Review Topic of the Week

Highlights •Ticagrelor is a cornerstone of antithrombotic therapy after ACS, but its effectiveness is limited by nonadherence. •Premature ticagrelor discontinuation occurs in 25% of patients and is related to adverse events. •The most frequent adverse events of ticagrelor are bleeding and dyspnea. •Appropriate patient selection, early follow-up, patient education, and appropriate bleeding prophylaxis can mitigate ticagrelor nonadherence.